The Platform Behind the Spray, and What Can Honestly Be Said About It

Hypospray® is a topical transdermal delivery platform — testosterone applied to the skin, absorbed through it, bypassing the liver. It is not nasal, not inhaled, and not injectable. Keen Testosterone Spray Rx uses it.

That last sentence is worth stating flatly, because "Hypospray" invites science-fiction associations that have nothing to do with what this is. It is a metered topical spray.

What the published record contains

Three peer-reviewed papers, cited by author and journal:

Pharmacokinetics in healthy males — a 2006 study in the British Journal of Clinical Pharmacology.[1]

Bioequivalence assessment corrected for endogenous testosterone — a 2009 study in the International Journal of Clinical Pharmacology and Therapeutics, comparing against AndroGel®.[2]

The delivery system with a percutaneous local anaesthetic — a 2006 study in Anaesthesia, examining the platform for venepuncture.[3] Evidence that the approach carries a different molecule is a real datapoint about the platform rather than about testosterone.

The detailed write-up is the published clinical evidence; the gaps are enumerated in the clinical case.

Where it sits in ninety years of delivery engineering

The constraint has not changed since 1935: oral testosterone is inactivated in the liver, so parenteral routes or molecular modifications are required.[4] Injection solved the liver and dosed at intervals. Patches solved the liver and irritated skin. Gels solved occlusion — dominating the transdermal market for patient acceptability and their non-occlusive nature[5] — and brought the transfer problem.

A metered topical spray is another position in that same trade space. It is not outside it, and this hub does not present it as an escape from the trade-offs — the framing is in the pharmacokinetic Goldilocks problem.

What using it does not change

The diagnostic requirement. Symptoms plus unequivocally, consistently low concentrations, confirmed on a repeat fasting morning measurement.[7] See why one low result doesn't mean low testosterone.

The target. Mid-normal.[7]

The monitoring. Symptoms, adverse effects, compliance, serum testosterone, hematocrit, prostate cancer risk in the first year.[7] See the 3-month panel.

The contraindications. Including fertility plans and elevated hematocrit.[7]

A delivery platform changes how the hormone gets in. It does not change who should be taking it or how they should be watched.

Frequently asked questions

Is Hypospray® injectable or nasal? Neither. It is a topical transdermal spray applied to the skin.

Is it better than a gel or an injection? The Endocrine Society guideline ranks no formulation, naming five factors to weigh.[7] The published evidence for this platform is pharmacokinetic.[1][2]

Do I still need transfer precautions? Yes, in full.[6]

What is the product called? Keen Testosterone Spray Rx. Details at /testosterone.

Where the story goes next

Ninety years from a molecule nobody could deliver to a metered topical dose. The remaining T Files seasons cover the state of modern practice and the dose question.

In the meantime: what higher doses buy you and how long TRT takes to work.

References

7 sources

1. Chik Z, Johnston A, Tucker AT, et al. Pharmacokinetics of a new testosterone transdermal delivery system, TDS®-testosterone in healthy males. Br J Clin Pharmacol. 2006;61(3):275–279. doi:10.1111/j.1365-2125.2005.02542.x · PMID 16487220
2. Chik Z, Johnston A, Tucker AT, et al. Correcting endogenous concentrations of testosterone influences bioequivalence and shows the superiority of TDS®-testosterone versus Androgel®. Int J Clin Pharmacol Ther. 2009;47(4):262–268. PMID 19356392
3. Tucker AT, Chik Z, Michaels L, et al. Study of a combined percutaneous local anaesthetic and the TDS® system for venepuncture. Anaesthesia. 2006;61(2):123–126. doi:10.1111/j.1365-2044.2005.04432.x · PMID 16430563
4. Nieschlag E, Nieschlag S. ENDOCRINE HISTORY: The history of discovery, synthesis and development of testosterone for clinical use. Eur J Endocrinol. 2019;180(6):R201–R212. doi:10.1530/EJE-19-0071 · PMID 30959485
5. Hadgraft J, Lane ME. Transdermal delivery of testosterone. Eur J Pharm Biopharm. 2015;92:42–48. doi:10.1016/j.ejpb.2015.02.015 · PMID 25709060
6. U.S. Food and Drug Administration. AndroGel (testosterone gel) 1% — prescribing information, including BOXED WARNING: secondary exposure to testosterone. Reference ID 021015s044. 2019. accessdata.fda.gov
7. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364